270 related articles for article (PubMed ID: 11440959)
1. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
2. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
4. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
5. CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.
Souiden Y; Mahdouani M; Chaieb K; Elkamel R; Mahdouani K
Cancer Epidemiol; 2011 Oct; 35(5):480-4. PubMed ID: 21193363
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
7. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
9. A polymorphism in CYP17 and endometrial cancer risk.
Haiman CA; Hankinson SE; Colditz GA; Hunter DJ; De Vivo I
Cancer Res; 2001 May; 61(10):3955-60. PubMed ID: 11358812
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
11. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
12. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
13. CYP17 gene polymorphism and its association in north Indian prostate cancer patients.
Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P
Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382
[TBL] [Abstract][Full Text] [Related]
14. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany.
Vesovic Z; Herkommer K; Vogel W; Paiss T; Maier C
Anticancer Res; 2005; 25(2B):1303-7. PubMed ID: 15865082
[TBL] [Abstract][Full Text] [Related]
15. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
16. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
[TBL] [Abstract][Full Text] [Related]
17. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
18. A polymorphism in the CYP17 gene and risk of prostate cancer.
Stanford JL; Noonan EA; Iwasaki L; Kolb S; Chadwick RB; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):243-7. PubMed ID: 11895872
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
20. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
